Staines Declaration Errata
`
`4/2/2018
`
`Errata to Staines Declaration of March 6,zOtB (Exhibit LL4OI
`
`il
`,1 I
`lty ÕJ
`,t lq
`
`Iaå
`
`ogzuÀ
`
`Paragraphl
`Page Footnote # L¡n
`3
`fn. 6
`4th Exhibit (2019). Cipla exclusively . . .
`Exhibit (2049). Cipla exclusively . . .
`4
`Last PTAB d¡d institute on October 27,2017
`lt4
`PTAB did institute on August 21,2017
`4
`3rd . . . entered on October 21.,2017, pp.26-
`fn.8
`entered on August 2I,2017, pp. 26-
`'J.4 fn.74
`1st Exhibit 1076 ar.p.24;
`Exhibit 1076 aÌ.p.26;
`16 Fn.27 1st See, e.q., Exh¡bit 1058 at p. 1; Exhibit 2067
`See, e.9., Exhibit 1058 at p. 2; Ëxhibit 2067
`20 Fn.43
`1st Grohomv.JohnDeere, Co.,383U.S. 1, 17-18(1966) Grahamv.JohnDeere,Co.,383U.S. 1, 17-18,36(1966)
`22 Fn.48
`5th
`even though he has done so for prescriptions
`. . . even though has done so for prescriptions
`23 Fn.49 2nd prescription growth rate based at least in part
`prescription growth rate+€s€C
`at least in part
`25 T25
`4th prescriptions annual dollar sales
`prescriptions and annual dollar sales
`43 Fn.97 3rd above, corticosteroids are generally not used
`above, oral corticosteroids are generally not used
`43 Fn. 100 1st . . . oral antihistamines were often deemed inadeq-
`. . . oral antihistamines alone were often deemed inadeq-
`51 Fn.123 2nd 18-19; Exhibit 2075aTp.2
`18-19; Exhibit 2075 aT p. 2; Exhibit 1092 at pp.46, 50
`l-st See, e.9., Exhibit 1075 at pp.2-3; ...
`61 Fn. 143
`See, e.9., Exhibit 1075 atpp.z-4;
`68
`3rd . . . 1) Duonase prescriptions and revenues
`f83
`1-) Duonase unit sales and revenues
`73
`fn.I7I
`Lst ... Exhibit 1118 at pp.24-26. Cipla specifical-
`Exhibit 1118 aT pp.24-26,36-37. Cipla specifical-
`88
`2nd . . . in the face of generic entry often by
`in the face of generic entry efte+ by
`1i109
`90
`fn.219 2nd Exhibit 1079 at pp.15,39,56; ...
`Exh¡bit 1079 at pp.15,39,56; .. .
`90Fn.22o1stExhibit2048atpp.131-132;Exhibit2053atp.I94;...@Exhibit2053atp.194;...
`91 Fn.22I 1st Exhibit 2053 at pp. L31-132; Exhibit tI22 at p.3
`Exhibit 2048 at pp. 131-132; Exhibit 1122arp.3
`92 Fn.226 1st See, e.9., Exhibit 1082 at pp. 2, 5-6; 17-18,78;
`See, e.9., Exhibit 1082 al pp.2,5-7; 17-18,78;
`9s
`last reimbursement for Dymista@ the applicable
`reimbursement for Dymista@ for the applicable
`11LL4
`98
`fn. 239 1st . . . Exhíbit 1089 at p. 1; Exhibit 1091, ar. p.22.
`Exhibit 1089 at p. 2; Exhibit 7097 ar p.22
`98
`fn.24l
`Exhibít 1100 at p p.6-7
`Exhibit 1100 aI pp. 1,6-7
`Lst
`Exhibit L089 at pp. 2-3; Exhibit 1069 at pp. 15,20; Exhibit
`99
`fn.244 1st Exhibit 1089 at p. 3;
`LO92 at pp. L6-L7; . . .
`99
`ll1-21 Last the drug.
`the drug.2aa" New fn. 244o: ld.
`100 1t1.2r
`10th blocked from reimbursement.2as lt does
`blocked from reimbursement.2as lt does not
`101 fn.25L
`Exhibit L089 at p. 2; Exhibit 1133 at p. 26
`1st
`Exhibit 1089 at
`2
`110 fn.275 Lst Exhibit 2064 at T21.
`Exh i bit 2064 at llll21.-22.
`1"I2 fn.279 1st . . . Exhibit 1134 at p. 50; Exhibit
`Exhibit 1"134 at p. 99; Exhibit 1136 at pp.9,25; Exhibit
`tl2
`fn. 280 1st . . . Exhibit 1134 at p.50.
`Exhibit 11"34 at p. 99.
`113 fn.286 2nd p.50.
`p. 99; Exhibit 1t37 atp.4.
`113 fn.289 1st Exhibit 1135 aTpp.26;
`Exhibit 1135 at pp. 26; Exhibit 1136 at p. 9;
`774 fn.290 Lst Exhibit 1138 at pp 6, 8-10. For examole. Mr
`Exhibit 1138 at pp. 6, 24-25. For example, Mr
`776 fn.293 1st Exhibit 9
`Exh i bít 9 pr€v¡d€s+h€-reports
`rovides the re
`these
`th ese
`
`